Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study

Abstract

Introduction. This study examined the influence of diabetes on left ventricular hypertrophy (LVH) detected by different electrocardiographic (ECG) criteria and its changes induced by a 12-month candesartan-based regimen.

Methods. The patients were treated for a 12-month period with a candesartan-based regimen (8/16 mg + hydrochlorothiazide12.5 mg + additional drugs to target blood pressure < 140/90 mmHg [< 130/80 in diabetics]). Cornell voltage index (CorV), Cornell product (CorP), Sokolow-Lyon voltage index (SokV), and Sokolow-Lyon product (SokP) were calculated. In total 276 patients were included, 51 with diabetes.

Results. At study end, blood pressure was reduced 19.0±9.2/7.3±3.4 mmHg in diabetic patients and 18.8±9.1/8.0±3.2 mmHg in non-diabetic subjects (both p<0.01 vs. baseline; p=0.85 between groups).At baseline, 37.5% of diabetic and 26.4% of non-diabetic patients fulfilled criteria of ECG-LVH by CorP (p=0.02), 25.7% and 23.2%, respectively, by SokP (p=0.18), 11.8% and 13.7% by CorV (p=0.16), and 14.3% and 11.6% by SokV (p=0.10).At study end, the prevalence of ECG-LVH was reduced to 25.1% (relative risk reduction [RRR] 33.3%, p=0.001) and 18.2% (RRR 29.2%, p=0.001) by CorP and SokP, in diabetic patients, respectively. In non-diabetic patients, only the CorP criterion showed a significant decrease (RRR 18.9%, p=0.01). No significant changes were observed by other criteria.The RRR of ECG-LVH with treatment was significantly higher in diabetics according to CorP and SokP criteria.

Conclusions. The prevalence of ECG-LVH detected by CorP was higher in diabetics. Diabetics achieved higher reductions in ECG-LVH prevalence than non-diabetics with a candesartan-based regimen.

Keywords

candesartan diabetes electrocardiogram left ventricular hypertrophy regression

Get full access to this article

View all access options for this article.

References

Bell DS Hypertension and diabetes: a toxic combination. Endocr Pract 2008;14:1031-9.

Umpierrez GE , Smiley D. , Robalino G. et al. Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in obese African-Americans with type 2 diabetes. J Clin Endocrinol Metab 2009;94:609-14.

Stratton IM , Cull CA , Adler AI , Matthews DR , Neil HA , Holman RR Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006;49:1761-9.

European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.

Barrios V. , Escobar C. , Calderon A. , Ribas L. , Marti D. , Asin E. Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press 2008;17:110-15.

Palmieri V. , Bella JN , Arnett DK et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 2001 ;103:102-07.

Dawson A. , Morris AD , Struthers AD The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus . Diabetologia 2005;48:1971-9.

Struthers AD , Morris AD Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002;359:1430-2.

Lindholm LH , Ibsen H. , Dahlöf B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.

10.

Levy D. , Salomon M. , D’Agostino RB , Belanger AJ , Kannel WB Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.

11.

Bella JN , Devereux RB

Is echocardiography essential in the management of newly diagnosed hypertension?

Am J Hypertens 2006;19:1156-7.

12.

Chobanian AV , Bakris GL , Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.

13.

Mancia G. , De Backer G. , Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) . J Hypertens 2007;25:1105-87.

14.

Okin PM , Devereux RB , Jern SS et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.

15.

Isobe N. , Taniguchi K. , Oshima S. et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J 2002;66:993-9.

16.

Barrios V. , Calderon A. , Escobar C. et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice. The SARA study. J Hypertens 2007;25:1967-73.

17.

Escobar C. , Barrios V. , Calderón A. et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA study. J Clin Hypertens 2008;10:208-14.

18.

Casale PN , Devereux RB , Kligfield P. et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol 1985;6:572-80.

19.

Okin PM , Roman MJ , Devereux RB , Pickering TG , Borer JS , Kligfield P. Time-voltage area of the 12-lead electrocardiogram. Detection of left ventricular hypertrophy. Hypertension 1998;31:937-42.

20.

Okin PM , Roman MJ , Devereaux RB , Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995;25:417-23.

21.

Alfakih K. , Walters K. , Jones T. , Ridgway J. , Hall AS , Sivananthan M. New gender-specific partition values for ECG criteria of left ventricular hypertrophy. Recalibration against cardiac MRI. Hypertension 2004;44:175-9.

22.

Barrios V. , Escobar C. , Calderón A. et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst 2006;7:236-42.

23.

Okin PM , Devereux RB , Harris KE et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2007;50:984-90.

24.

Verdecchia P. , Reboldi G. , Angeli F. et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.

25.

Galderisi M. , Anderson KM , Wilson PW , Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991;68:85-9.

26.

Barrios V. , Escobar C. , Calderon A. et al. Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study. Heart Vessels 2009;(In press).

27.

Okin PM , Devereux RB , Gerdts E. et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006;113:1588-96.

28.

Barrios V. , Escobar C. , Calderón A. , Vegazo O. , Fernandez R. , Asín E. Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice. Diabetes Res Clin Pract 2007;77:492-3.

29.

Okin PM , Devereux RB , Jern S. , Kjeldsen SE , Julius S. , Dählof B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 2000;36:766-73.